经口激光显微手术治疗75岁以上声门癌
这项回顾性病例系列纳入134例75岁以上、接受二氧化碳经口激光显微手术(CO2 TOLMS)的Tis-T3期声门型喉鳞状细胞癌患者,未观察到治疗相关死亡。5年总生存率68.9%、疾病特异性生存率95.4%、无复发生存率79.5%、无喉食管功能障碍生存率66%、器官保留率92.5%。年龄和合并症与总生存及无喉食管功能障碍生存相关,但不是并发症的显著危险因素。
要点
- CO2 TOLMS治疗高龄Tis-T3声门癌肿瘤学结果良好
- 5年器官保留率92.5%,无治疗相关死亡
- 年龄和合并症不是术后并发症的显著危险因素
核心结论
- CO2 TOLMS对经过选择的Tis-T3期声门型喉鳞状细胞癌老年患者是可选治疗方式,肿瘤学结果良好且创伤小。
研究设计与样本
- 单中心三级学术机构回顾性病例系列,纳入1997至2017年接受CO2 TOLMS的Tis-T3期声门型喉鳞状细胞癌患者134例。
- 患者平均年龄80±4岁,中位年龄79岁,范围75-93岁。
主要发现
- 肿瘤分期分布为pTis 7例、pT1a 65例、pT1b 22例、pT2 35例、pT3 5例。
- 5年总生存率68.9%、疾病特异性生存率95.4%、无复发生存率79.5%、无喉食管功能障碍生存率66%、器官保留率92.5%。
- 年龄和合并症与总生存及无喉食管功能障碍生存相关,但不是并发症的显著危险因素。
- 较晚的T分期与总生存、疾病特异性生存、无复发生存、无喉食管功能障碍生存及器官保留均呈负相关。
临床怎么用
- 对于经过选择的75岁以上Tis-T3期声门型喉鳞状细胞癌患者,可考虑CO2 TOLMS作为一种微创治疗选择。
- 评估高龄患者时应关注年龄和合并症对总生存及喉食管功能的影响,但无需将其视为术后并发症的绝对禁忌。
局限性
- 研究为单中心回顾性病例系列,证据等级为4级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Laryngeal squamous cell carcinoma (LSCC) has a non-negligible incidence in elderly patients. However, there is still no clear indication on the ideal treatment for early-intermediate glottic LSCC in this specific age group. Both surgical and nonsurgical approaches may be burdened by complications and sequelae that negatively impact patient's health. In this setting, carbon dioxide transoral laser microsurgery (CO2 TOLMS) is a promising minimally invasive treatment option. STUDY DESIGN: Retrospective case series in a single tertiary academic institution. METHODS: Patients who underwent CO2 TOLMS for Tis-T3 glottic LSCC from 1997 to 2017 were reviewed. Demographic, clinical, and tumor characteristics, as well as postoperative complications were recorded. Overall (OS), disease-specific (DSS), recurrence-free (RFS), laryngo-esophageal dysfunction free survivals (LEDFS), and organ preservation (OP) were calculated. RESULTS: A total of 134 patients (mean age, 80 ± 4 years; median, 79; range, 75-93) were included in the study. Seven lesions were classified as pTis, 65 as pT1a, 22 as pT1b, 35 as pT2, and 5 as pT3. No treatment-related death was observed. Twenty-eight (20.9%) patients reported 10 surgical and 19 medical complications. Five-year OS, DSS, RFS, LEDFS, and OP were 68.9%, 95.4%, 79.5%, 66%, and 92.5%, respectively. Age and comorbidities were associated with OS and LEDFS. Advanced T categories were negatively correlated with OS, DSS, RFS, LEDFS, and OP. Age and comorbidities were not significant risk factors for complications. CONCLUSIONS: CO2 TOLMS can be considered a valuable therapeutic approach for selected Tis-T3 glottic LSCC even in the elderly given its favorable oncologic outcomes and minimal aggressiveness. LEVEL OF EVIDENCE: 4 Laryngoscope, 132:135-141, 2022.
引用
- Paderno A, Lancini D, Bosio P, et al. Transoral Laser Microsurgery for Glottic Cancer in Patients Over 75 Years Old. Laryngoscope. 2021. PMID: 34233029. doi:10.1002/lary.29738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。